3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Broncus Holding's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -97.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Broncus Holding's 3-Year ROIIC % or its related term are showing as below:
HKSE:02216's 3-Year ROIIC % is ranked worse than 83.66% of 820
companies
in the Medical Devices & Instruments industry
Industry Median: -1.765
vs HKSE:02216: -97.21
Broncus Holding 3-Year ROIIC % Historical Data
The historical data trend for Broncus Holding's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Broncus Holding's 3-Year ROIIC %
For the Medical Devices subindustry, Broncus Holding's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding's 3-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Broncus Holding's 3-Year ROIIC % falls into.
Broncus Holding 3-Year ROIIC % Calculation
Broncus Holding's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Broncus Holding 3-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Broncus Holding's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02216 has been successfully added to your 